Metastatic basal cell carcinoma with a high tumor mutational burden that achieved complete response with pembrolizumab

被引：1
|
作者：
Yamakawa, Kohei [1 ]
Ogata, Dai [1 ]
Hiki, Kojiro [1 ]
Jinnai, Shunichi [1 ]
Namikawa, Kenjiro [1 ]
Takahashi, Akira [1 ]
Yamazaki, Naoya [1 ]
机构：
[1] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2023年 / 62卷 / 02期
关键词：
D O I：
10.1111/ijd.16245
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E79 / E80
页数：2
相关论文
共 50 条
  • [1] Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab
    Uehara, Sanae
    Naganuma, Atsushi
    Furuichi, Nozomi
    Furusawa, Ai
    Kaburagi, Takuya
    Naruse, Hiroaki
    Tomaru, Shota
    Sano, Nozomi
    Suzuki, Yuhei
    Masuda, Tomoyuki
    Hoshino, Takashi
    Yasuoka, Hidetoshi
    Tanaka, Yuko
    Saito, Shuichi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    INTERNAL MEDICINE, 2023, 62 (21) : 3151 - 3156
  • [2] Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports
    Mota, Jose Mauricio
    Sousa, Luana Guimaraes
    Braghiroli, Maria Ignez
    Siqueira, Luiz Tenorio
    Bezerra Neto, Joao Evangelista
    Chapchap, Paulo
    de Oliveira Hoff, Ana A.
    Hoff, Paulo M.
    MEDICINE, 2018, 97 (52)
  • [3] Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report
    Jin, Jing
    Yang, Qidong
    Yu, Yangyang
    Chen, Lin
    Pan, Shouhua
    ANTI-CANCER DRUGS, 2023, 34 (04) : 595 - 598
  • [4] Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment
    Jin, Jing
    Li, Junlong
    Peng, Chao
    Chen, Jiajun
    Xu, Gang
    Pan, Shouhua
    ANTI-CANCER DRUGS, 2023, 34 (06) : 797 - 802
  • [5] Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden
    Sasaki, Akinori
    Nakajima, Satoru
    Motomura, Yasuaki
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (04) : 1628 - 1633
  • [6] Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC).
    Maia, Manuel C.
    Almeida, Lorena
    Bergerot, Paulo Gustavo
    Dizman, Nazli
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [7] Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden
    Abudalou, Mohammad
    Vega, Eduardo A.
    Kondratiev, Svetlana
    Conrad, Claudius
    Kozyreva, Olga
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (12)
  • [8] Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report
    LhU, Baorang
    Liu, Ying
    Li, Jing
    Diao, Liyan
    Shao, Lin
    Han Han-Zhang
    Zhang, Lu
    Kang, Qiaolin
    Yang, Wuwei
    ONCOLOGIST, 2020, 25 (01): : 15 - 18
  • [9] Complete response of metastatic Merkel cell carcinoma under treatment with Pembrolizumab
    Koechel, A.
    Wilhelmi, J.
    Garbe, C.
    Eigentler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 79 - 80
  • [10] Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma
    Kazuki Shimizu
    Satoshi Tamada
    Yudai Matsuoka
    Ishun Go
    Satoshi Okumura
    Masao Ogawa
    Tetsuji Ohmachi
    International Cancer Conference Journal, 2022, 11 : 205 - 209
12345